HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, 7616914111, Iran.
Pharmaceutics Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.
BMC Complement Med Ther. 2023 Feb 7;23(1):41. doi: 10.1186/s12906-023-03869-1.
The concurrent usage of herbal medicines with conventional therapies is an important concern in cancer treatment which can lead to unexpected consequences like herb-drug interactions. This study aimed to determine the prevalence of potential herb-drug interactions and to predict factors associated with herb-drug interactions for cancer patients.
This cross-sectional study was conducted among a convenience sample of 315 cancer patients referring to the oncology clinics of Kerman city in 2018. Data were collected via comprehensive face-to-face interviews and medical chart reviews. A drug interaction checker was used to determine herb-drug interactions. The information of patients was compared based on herb-drug interactions using bivariable logistic regression models, and predictors were determined by the multivariable logistic regression model. All analyses were performed by Stata software version 16.
Of 262 patients (83.2% of the patients) who used herbal medicines, 209 patients [79.8% (95% Confidence Intervals (CI): 75.2 - 85.1)] had potential herb-drug interactions. Chamomile was the most popular herbal medicine (n = 163, 78.0%), and minor and moderate herb-drug interactions were caused by green tea (n = 34, 16.3%) and peppermint (n = 78, 37.5%). The number of chemotherapeutic agents (OR: 1.92, 95% CI: 1.43-2.58; P-value < 0.0001) and the experienced of pain during chemotherapy courses (OR = 2.22, 95%CI:1.00-4.94; P-value = 0.04) were some of the predictors of herb-drug interactions among cancer patients.
Herbal medicine use during chemotherapy was found prevalent among cancer patients; of them, the experience of potential herb-drug interactions was highly frequent. Oncologists and clinical pharmacologists are recommended to take into account challenges associated with herb-drug interactions in their routine practices, particularly during chemotherapy among these patients.
在癌症治疗中,草药与常规疗法同时使用是一个重要问题,可能会导致草药-药物相互作用等意外后果。本研究旨在确定癌症患者中潜在草药-药物相互作用的发生率,并预测与草药-药物相互作用相关的因素。
本横断面研究于 2018 年在克尔曼市肿瘤诊所对 315 例癌症患者进行了便利抽样。通过全面的面对面访谈和病历回顾收集数据。使用药物相互作用检查器来确定草药-药物相互作用。根据草药-药物相互作用,通过双变量逻辑回归模型比较患者信息,并通过多变量逻辑回归模型确定预测因子。所有分析均使用 Stata 软件版本 16 进行。
在 262 例(83.2%的患者)使用草药的患者中,有 209 例(95%置信区间(CI):75.2-85.1)存在潜在草药-药物相互作用。甘菊是最受欢迎的草药(n=163,78.0%),绿茶(n=34,16.3%)和薄荷(n=78,37.5%)引起轻微和中度草药-药物相互作用。化疗药物的数量(OR:1.92,95%CI:1.43-2.58;P 值<0.0001)和化疗过程中经历疼痛(OR=2.22,95%CI:1.00-4.94;P 值=0.04)是癌症患者发生草药-药物相互作用的一些预测因子。
在化疗期间使用草药在癌症患者中很常见;其中,潜在草药-药物相互作用的经验发生率很高。建议肿瘤学家和临床药理学家在常规实践中考虑与草药-药物相互作用相关的挑战,特别是在这些患者的化疗期间。